Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
2019 |
| gptkbp:ATCCode |
L01EM03
|
| gptkbp:brand |
gptkb:Piqray
|
| gptkbp:CASNumber |
1217486-61-7
|
| gptkbp:chemicalFormula |
C19H22F3N5O2
|
| gptkbp:contraindication |
hypersensitivity to alpelisib
|
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:eliminationHalfLife |
8-9 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alpelisib
|
| gptkbp:indication |
HR-positive, HER2-negative advanced or metastatic breast cancer
|
| gptkbp:KEGGID |
gptkb:D10841
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
PI3K inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
441.4 g/mol
|
| gptkbp:PubChem_CID |
25262016
CHEMBL2364608 DB12034 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue rash hyperglycemia |
| gptkbp:synonym |
gptkb:BYL719
|
| gptkbp:target |
gptkb:PIK3CA
|
| gptkbp:UNII |
Q1J0XQF478
|
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|